Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs

European Journal of Pharmacology

Volumn 720, Issue 1-3, 2013, Pages 29-37

  Nogawa, Hisashi ^a   Kawai, Tomoyuki ^a   Yajima, Miho ^a   Miura, Masahiro ^a   Ogawa, Tetsurou ^a   Murakami, Kouji ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Conscious dogs; hERG expression inhibitor; Probucol; QT interval prolongation

Indexed keywords

MOXIFLOXACIN; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BEAGLE; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROCARDIOGRAPHY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; QT INTERVAL; QT PROLONGATION; SINGLE DRUG DOSE; TIMED DRUG RELEASE;

CONSCIOUS DOGS; HERG EXPRESSION INHIBITOR; PROBUCOL; QT INTERVAL PROLONGATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZA COMPOUNDS; DOGS; DRUG INTERACTIONS; ETHER-A-GO-GO POTASSIUM CHANNELS; LONG QT SYNDROME; MALE; PROBUCOL; QUINOLINES;

EID: 84890114615     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.10.056     Document Type: Article

References (35)

1. Ks, beta-adrenoceptor stimulation, pacing rate and gender Br. J. Pharmacol. 147 2006 653 660
2. + channel blockade by the fluoroquinolone antibiotic moxifloxacin Br. J. Pharmacol. 147 2006 905 916
3. M.M. Buckley, K.L. Goa, A.H. Price, and R.N. Brogden Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia Drugs 37 1989 761 800
4. X. Chen, J.D. Cass, J.A. Bradley, C.M. Dahm, Z. Sun, E. Kadyszewski, M.J. Engwall, and J. Zhou QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome Br. J. Pharmacol. 146 2005 792 799 (Pubitemid 41622245)
5. J.S. Cordes, Z. Sun, D.B. Lloyd, J.A. Bradley, A.C. Opsahl, M.W. Tengowski, X. Chen, and J. Zhou Pentamidine reduces hERG expression to prolong the QT interval Br. J. Pharmacol. 145 2005 15 23 (Pubitemid 40675544)
6. L.X. Cubeddu Iatrogenic QT abnormalities and fatal arrhythmias: mechanisms and clinical significance Curr. Cardiol. Rev. 5 2009 166 176
7. R. Dixon, S. Job, R. Oliver, D. Tompson, J.G. Wright, K. Maltby, U. Lorch, and J. Taubel Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects Br. J. Clin. Pharmacol. 66 2008 396 404
8. M.D. Eisenhauer, A.H. Eliasson, A.J. Taylor, P.E. Coyne Jr., and D.C. Wortham Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients Chest 105 1994 389 395
9. E. Ficker, A.T. Dennis, L. Wang, and A.M. Brown Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG Circ. Res. 92 2003 e87 e100
10. E. Ficker, Y.A. Kuryshev, A.T. Dennis, C. Obejero-Paz, L. Wang, P. Hawryluk, B.A. Wible, and A.M. Brown Mechanisms of arsenic-induced prolongation of cardiac repolarization Mol. Pharmacol. 66 2004 33 44 (Pubitemid 38822085)
11. Kr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes J. Pharmacol. Exp. Ther. 321 2007 911 920 (Pubitemid 46762679)
12. J. Guo, X. Li, H. Shallow, J. Xu, T. Yang, H. Massaeli, W. Li, T. Sun, G.N. Pierce, and S. Zhang Involvement of caveolin in probucol-induced reduction in hERG plasma-membrane expression Mol. Pharmacol. 79 2011 806 813
13. K. Hayashi, M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, N. Hoshi, H. Higashida, N. Terashima, Y. Uno, H. Kanaya, and H. Mabuchi Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG Clin. Sci. 107 2004 175 182 (Pubitemid 39070934)
14. J.F. Heeg, and H. Tachizawa [Plasma levels of probucol in man after single and repeated oral doses (author's transl)] Nouv. Presse. Med. 9 1980 2990 2994 (Pubitemid 10029353)
15. H.H. Holzgrefe, I. Cavero, and C.R. Gleason Analysis of the nonclinical telemetered ECG: impact of logging rate and RR bin width in the dog and cynomolgus monkey J. Pharmacol. Toxicol. Methods 56 2007 34 42 (Pubitemid 46829927)
16. H.H. Holzgrefe, I. Cavero, C.R. Gleason, W.A. Warner, L.V. Buchanan, M.W. Gill, D.E. Burkett, and S.K. Durham Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys J. Pharmacol. Toxicol. Methods 55 2007 159 175 (Pubitemid 46227991)
17. Ks in human ventricular muscle Circulation 112 2005 1392 1399 (Pubitemid 41291763)
18. Y.A. Kuryshev, E. Ficker, L. Wang, P. Hawryluk, A.T. Dennis, B.A. Wible, A.M. Brown, J. Kang, X.L. Chen, K. Sawamura, W. Reynolds, and D. Rampe Pentamidine-induced long QT syndrome and block of hERG trafficking J. Pharmacol. Exp. Ther. 312 2005 316 323 (Pubitemid 40096484)
19. K. Kuwano, J. Matsuo, S. Ohkuma, M. Ban, A. Suzuki, T. Kamenosono, T. Sukamoto, K. Fukuzaki, and R. Nagata Effects of pentamidine on QT interval and ether-a-go-go related gene expression in cynomolgus monkeys J. Pharmacol. Toxicol. Methods 64 2011 e46
20. Ks) fails to lengthen rabbit ventricular muscle QTc and action potential duration Br. J. Pharmacol. 132 2001 101 110 (Pubitemid 32140472)
21. H. Linnebjerg, M. Seger, P.A. Kothare, T. Hunt, A.M. Wolka, and M.I. Mitchell A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects Int. J. Clin. Pharmacol. Ther. 49 2011 594 604
22. H. Matsuhashi, S. Onodera, Y. Kawamura, N. Hasebe, C. Kohmura, H. Yamashita, and K. Tobise Probucol-induced QT prolongation and torsades de pointes Jpn. J. Med. 28 1989 612 615 (Pubitemid 19272940)
23. + channel block and disruption of protein trafficking by fluoxetine and norfluoxetine Br. J. Pharmacol. 149 2006 481 489 (Pubitemid 44658508)
24. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45 (Pubitemid 36351620)
25. M.C. Sanguinetti, and M. Tristani-Firouzi hERG potassium channels and cardiac arrhythmia Nature 440 2006 463 469
26. N. Sarapa, D.J. Nickens, S.R. Raber, R.R. Reynolds, and M.A. Amantea Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies Clin. Pharmacol. Ther. 83 2008 153 159
27. Ks by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles Br. J. Pharmacol. 148 2006 255 263 (Pubitemid 43801172)
28. D.F. Steele, J. Eldstrom, and D. Fedida Mechanisms of cardiac potassium channel trafficking J. Physiol. 582 2007 17 26 (Pubitemid 46993558)
29. S.M. Straus, M.C. Sturkenboom, G.S. Bleumink, J.P. Dieleman, J. van der Lei, P.A. de Graeff, J.H. Kingma, and B.H. Stricker Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death Eur. Heart J. 26 2005 2007 2012 (Pubitemid 41435722)
30. M. Tamura, Y. Ueki, E. Ohtsuka, M. Oribe, M. Seita, K. Oribe, and M. Ito Probucol-induced QT prolongation and syncope Jpn. Circ. J. 58 1994 374 377 (Pubitemid 24220354)
31. T. Taniguchi, M. Uesugi, T. Arai, T. Yoshinaga, N. Miyamoto, and K. Sawada Chronic probucol treatment decreases the slow component of the delayed-rectifier potassium current in CHO cells transfected with KCNQ1 and KCNE1: a novel mechanism of QT prolongation J. Cardiovasc. Pharmacol. 59 2012 377 386
32. Ks to canine ventricular repolarization: key role for beta-adrenergic receptor stimulation Circulation 107 2003 2753 2760 (Pubitemid 36667252)
33. B.A. Wible, P. Hawryluk, E. Ficker, Y.A. Kuryshev, G. Kirsch, and A.M. Brown HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk J. Pharmacol. Toxicol. Methods 52 2005 136 145 (Pubitemid 41008637)
34. Y.G. Yap, and A.J. Camm Drug induced QT prolongation and torsades de pointes Heart 89 2003 1363 1372 (Pubitemid 37311108)
35. H. Yokoyama, Y. Nakamura, H. Iwasaki, Y. Nagayama, K. Hoshiai, Y. Mitsumori, and A. Sugiyama Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs J. Pharmacol. Sci. 110 2009 476 482